Negative HPV tests were more predictive than negative cytology tests for absence of cancer.
Current screening guidelines for cervical cancer recommend either cytology testing or co-testing with cytology and human papillomavirus (HPV). How do screening programs that rely on HPV testing compare with those that use only cytology or co-testing? Investigators reported their observations based on almost 1 million women (age range, 30–64) enrolled in the Kaiser Permanente healthcare system who underwent routine successive screening with either cytologic testing or co-testing from 2003 to 2014.
Risk for cervical intraepithelial neoplasia 3+ (CIN grade 3, adenocarcinoma in situ, or cervical cancer) decreased with each successive screening interval. However, the reduction in risk for CIN3+ was greater following a negative HPV test (even at a…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)